Ascentage Pharma's APG-3288 Receives FDA Clearance for Clinical Study

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Jan 07 2026

0mins

Ascentage Pharma announced that its novel next-generation BTK-targeted protein degrader, APG-3288, has received the IND clearance from the U.S. Food and Drug Administration and is poised to enter a clinical study in patients with relapsed/refractory B-cell malignancies. This clearance officially opens the chapter on Ascentage Pharma's clinical development in the field of targeted degradation and marks another major expansion to the company's global innovative pipeline, the company said. This is a global, multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies.

AAPG

$28.32+Infinity%1D

Analyst Views on AAPG

Wall Street analysts forecast AAPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG is 48.50 USD with a low forecast of 45.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Analyst Rating

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 27.770

Low

45.00

Averages

48.50

High

51.00

Current: 27.770

Low

45.00

Averages

48.50

High

51.00

Lucid Capital

NULL

Buy

initiated

$50

Al Analysis

2025-12-15

Reason

Lucid Capital

Price Target

$50

Al Analysis

2025-12-15

initiated

NULL

Buy

Reason

Lucid Capital initiated coverage of Ascentage Pharma with a Buy rating and $50 price target. The firm says Ascentage is a commercial-stage biotechnology company focused on developing next generation tyrosine kinase inhibitors for oncology. The company has the potential to develop and commercialize "differentiated" assets with validated targets in multi-blockbuster opportunities, offering significant upside for somewhat mitigated risk, the analyst tells investors in a research note.

Oppenheimer

Matthew Biegler

Outperform

initiated

$45

2025-12-04

Reason

Oppenheimer

Matthew Biegler

Price Target

$45

2025-12-04

initiated

Outperform

Reason

Oppenheimer analyst Matthew Biegler initiated coverage of Ascentage Pharma with an Outperform rating and $45 price target. The firm believes Ascentage has the potential to become the next BeOne. To get there, they're taking a page from BeOne's playbook. Better drugs, focusing on chronic blood cancers with large TAMs, Oppenheimer argues, adding that olverembatinib looks like a best-in-class BCR-ABL inhibitor. Separately, Ascentage's BCL-2 inhibitor lisaftoclax is taking aim at BeOne's biggest market: Chronic Lymphocytic Leukemia. The firm believes lisaftoclax' tolerability could enable it to make inroads into an indication where other BCL-2 inhibitors have failed, namely Myelodysplastic syndrome.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AAPG

Unlock Now

Truist

Gregory Renza

Buy

initiated

$51

2025-11-24

Reason

Truist

Gregory Renza

Price Target

$51

2025-11-24

initiated

Buy

Reason

Truist analyst Gregory Renza initiated coverage of Ascentage Pharma with a Buy rating and $51 price target. The company's Lisaftoclax is differentiated by improved tolerability and accelerated 5-day dose ramp-up, which is clinically meaningful, according to key opinion leaders, the analyst tells investors in a research note. Growth in China depends on the NRDL inclusion by the end of 2027, and the firm views GLORA's readout 2025-end or 2026E as key to supporting U.S. expansion in second-line CLL/SLL, or chronic lymphocytic leukemia/small lymphocytic lymphoma, the firm added.

BTIG

Buy

initiated

$50

2025-11-10

Reason

BTIG

Price Target

$50

2025-11-10

initiated

Buy

Reason

BTIG initiated coverage of Ascentage Pharma with a Buy rating and $50 price target. The firm says Ascentage has a "validated" apoptosis-targeted platform and two late-stage assets, Olverembatinib and Lisaftoclax, to drive sustained commercial growth and valuation upside. BTIG views Ascentage as one of the "most compelling" China-based biopharma stocks. The company is positioned to for "sustainable global relevance" as it transitions from clinical-stage to commercial-scale, the analyst tells investors in a research note.

About AAPG

Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.